Neurological theory of hypertension

Medical Hypotheses

Volumn 60, Issue 6, 2003, Pages 852-855

  Eggers, Arnold E ^a  

^a Downstate Health Sciences University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; CHOLESTEROL; ETHOSUXIMIDE; GLUCOCORTICOID; GLUCOSE; HYDROCORTISONE; VALPROIC ACID; ZONISAMIDE;

ADRENERGIC SYSTEM; ANXIETY; DORSAL RAPHE NUCLEUS; HUMAN; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INCIDENCE; MEDITATION; MIGRAINE; MORBIDITY; NERVOUS SYSTEM; PACEMAKER NERVE CELL; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STRESS; THEORY;

EID: 0037410471     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(03)00059-8     Document Type: Review

References (21)

1. Eggers A. E. New neural theory of migraine. Med Hypotheses 2001; 56: 360-363.
2. Janeway T. C. Arch Intern Med 1913; 12: 755, Note: this historical reference was not inspected; however, it is extensively discussed in references 3 and 6.
3. Gardner J. W., Mountain G. E., Hines E. A. The relationship of migraine to hypertension and to hypertension headaches. Am J Med Sci 1940; 200: 5-53.
4. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia, and facial pain. Cephalalgia 1988; 8(suppl. 7): 1-96.
5. Davidoff R. A. In: Migraine: Manifestations, Pathogenesis, and Management. Philadelphia, PA: F.A. Davis Co., 2000: 10.
6. Walker C. H. Migraine and its relationship to hypertension. Br Med J 1959; 2: 1430-1433.
7. Kaplan N. M., Lieberman E. In: Clinical Hypertension. Baltimore, MD: Williams and Wilkins, 1998: 123.
8. Davidoff R. A. In: Migraine: Manifestations, Pathogenesis, and Management. Philadelphia, PA: F.A. Davis Co., 2000: 23. see also p. 60.
9. Timio M., Verdecchia P., Venanzi S., Gentili S., Ronconi M., Francucci B., Montanari M., Bichisao E. Age and blood pressure changes. A 20-year follow-up study in nuns in a secluded order. Hypertension 1988; 12: 457-461.
10. Cobb S., Rose R. M. Hypertension, peptic ulcer, and diabetes in air traffic controllers. JAMA 1973; 224: 489-492.
11. Perez L. H., Gurierrez L. A., Vioque J., Torres Y. Relation between overweight, diabetes, stress and hypertension: a case-controlled study in Yarumal-Antioquia, Colombia. Eur J Epidemiol 2001; 17: 275-280.
12. Habib K. E., Gold P. W., Chrousos G. P. Neuroendocrinology of stress. Neuroendocrinology 2001; 30: 695-728.
13. Bremmer J. D. Structural changes in the brain in depression and relationship to symptom recurrence. CNS Spectrums 2002; 7: 129-139.
14. Chrousos G. P. The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes. Int J Obesity 2000; 24(suppl. 2): S50-S55.
15. Davidoff R. A. In: Migraine: Manifestations, Pathogenesis, and Management. Philadelphia, PA: F.A. Davis Co., 2000: 60.
16. Stefan H., Snead O. C. Absence seizures. In: J. Engel, T. A. Pedley (eds). Epilepsy. Philadelphia, PA: Lippincott-Raven, 1998: 579-590.
17. Llinas R. L. The intrinsic electrophysiological properties of mammalian neurons: insights into central nervous system function. Science 1988; 242: 1654-1664.
18. Rho J. R., Sankar R. The pharmacological basis of anti-epileptic drug action. Epilepsia 1999; 40: 1471-1483.
19. Mathew N. T. Antiepileptic drugs in migraine prevention. Headache 2001; 41(suppl. 1): 18-24.
20. Eggers A. E., Moreno H. Suggestion for another anti-epileptic drug to use for migraine prophylaxis. Letter to the Editor; Headache 2002; 42: 696-697.
21. Pope H. G., McElroy S. L. Valproate. In: H. I. Kaplan, B. I. Sadock (eds). Comprehensive Textbook of Psychiatry. Baltimore, MD: Williams and Wilkins, 1995: 2112-2120.